PPD inks deal with China’s HLT to create data science-driven research solutions

Handshake business deal executives
Pharmaceutical Product Development inked a deal with China’s Happy Life Tech to develop data science-driven research solutions for the country’s growing drug development market. (Pixabay)

Pharmaceutical Product Development (PPD), a North Carolina-based CRO, has inked a deal with China’s Happy Life Tech (HLT) to develop data science-driven research solutions for the country’s growing drug development market.

Financial terms of the collaboration were not disclosed.

The partnership will focus on data-driven feasibility, patient recruitment and real-world evidence offerings for both global and China-based pharma and biotech companies. Combined, the two companies will offer services that are powered by HLT’s AI and data tech with PPD’s extensive expertise in clinical trial management and evidence generation. HLT boasts a network of physicians at more than 100 hospitals in 22 Chinese provinces.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

“Our focus on sites with access to eligible patients is designed to speed patient recruitment at high-performing sites and to more effectively incorporate Chinese patients into global trials,” David Simmons, chairman and CEO of PPD, said in a statement. “We will help clients adapt study protocols to the China market, while helping sites enhance quality, drive performance and lead global multicenter trials.”

PPD has nearly 20 years of extensive experience in Asia-Pacific and provides a broad range of Phase I-IV services in the region. The company has clinical trial operations based in Beijing and Shanghai and central laboratory facilities in Shanghai.

Read more on

Suggested Articles

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita.

Decentralized study company Medable has raised a large $91 million funding round as it continues to ramp up the deals in 2020.

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.